Transfer factor in the treatment of herpes simplex types 1 and 2.
Transfer factor potentiates cellular immunity and induces interferon. It was because of these properties that transfer factor was tried in 17 patients with recurrent herpes simplex types 1 and 2. Transfer factor was administered in doses ranging from 5 to 10 U/m2 i. m. The interval between injections varied from 1 week to 3 months. 16 patients could be evaluated clinically in whom the recurrence rate decreased from 10.7 +/- 6.1 to 2.1 +/- 2.5 (mean SD). The reduction was statistically significant. 8 patients were completely free of disease while the other 8 had reduced number of episodes during the period of observation, 7 patients had abnormal T cell function as reflected by the low number of T cells or low lymphocyte transformation. Statistically significant improvement in the T cell function was observed. Delayed hypersensitivity skin test reactions also improved significantly.
D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D013283:Stomatitis, Herpetic / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor